Gilead Sciences Sets Collaboration With Nurix Therapeutics

Gilead Sciences Sets Collaboration With Nurix Therapeutics

June 20, 2019 304

Gilead Sciences Inc. (GILD) on Wednesday said it would collaborate with privately held biotechnology company Nurix Therapeutics Inc. to develop new therapies for cancer and other diseases.

Gilead said it will make an upfront payment of $45 million to Nurix, which is working to discover drugs that harness the body's natural process to control protein levels.

San Francisco-based Nurix will also be eligible for up to roughly $2.3 billion in additional milestone payments, along with royalties on product sales, Gilead said.

The Foster City, Calif., biopharmaceutical company said it will have an option to license drug candidates directed to up to five targets resulting from its work with Nurix, which is backed by life-science investors Third Rock Ventures and Column Group.


 

Write to Colin Kellaher at colin.kellaher@wsj.com

 

 

Information source: here

Block ?

If this page is in your subscriptions, then it will be removed. You will not see this page. If you want to unblock a user, go to the settings, the list of blocked users and click unblock

Complain

The user will not know who exactly sent the complaint

Delete Company

The user will not know who exactly sent the complaint

Notifications

You Have 112 readed notifications

CHATS

Select chat category

×